Loading clinical trials...
Loading clinical trials...
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SUNRISE)
Conditions
Interventions
Tezepelumab
Placebo
Locations
64
United States
Research Site
Newport Beach, California, United States
Research Site
Denver, Colorado, United States
Research Site
Newark, Delaware, United States
Research Site
Hialeah, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Lincoln, Nebraska, United States
Start Date
August 9, 2022
Primary Completion Date
March 24, 2025
Completion Date
March 24, 2025
Last Updated
April 9, 2025
NCT06979323
NCT07431021
NCT06664619
NCT07383896
NCT06003569
NCT07282886
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions